ADC Therapeutics (ADCT) Competitors $3.16 -0.14 (-4.24%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$3.22 +0.06 (+2.06%) As of 07/11/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADCT vs. NTLA, AMPH, WVE, AUPH, ARDX, ELVN, VERV, NAGE, DYN, and CDTXShould you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Intellia Therapeutics (NTLA), Amphastar Pharmaceuticals (AMPH), WAVE Life Sciences (WVE), Aurinia Pharmaceuticals (AUPH), Ardelyx (ARDX), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), Niagen Bioscience (NAGE), Dyne Therapeutics (DYN), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry. ADC Therapeutics vs. Its Competitors Intellia Therapeutics Amphastar Pharmaceuticals WAVE Life Sciences Aurinia Pharmaceuticals Ardelyx Enliven Therapeutics Verve Therapeutics Niagen Bioscience Dyne Therapeutics Cidara Therapeutics ADC Therapeutics (NYSE:ADCT) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Does the media favor ADCT or NTLA? In the previous week, Intellia Therapeutics had 3 more articles in the media than ADC Therapeutics. MarketBeat recorded 5 mentions for Intellia Therapeutics and 2 mentions for ADC Therapeutics. Intellia Therapeutics' average media sentiment score of 0.58 beat ADC Therapeutics' score of 0.34 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ADCT or NTLA? ADC Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Is ADCT or NTLA more profitable? ADC Therapeutics has a net margin of -197.64% compared to Intellia Therapeutics' net margin of -1,154.10%. ADC Therapeutics' return on equity of 0.00% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ADC Therapeutics-197.64% N/A -45.57% Intellia Therapeutics -1,154.10%-56.06%-44.25% Do insiders and institutionals hold more shares of ADCT or NTLA? 41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 5.4% of ADC Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts rate ADCT or NTLA? ADC Therapeutics presently has a consensus target price of $7.75, suggesting a potential upside of 145.25%. Intellia Therapeutics has a consensus target price of $33.37, suggesting a potential upside of 189.41%. Given Intellia Therapeutics' higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than ADC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65 Which has better earnings & valuation, ADCT or NTLA? ADC Therapeutics has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADC Therapeutics$70.84M4.42-$157.85M-$1.45-2.18Intellia Therapeutics$45.57M26.21-$519.02M-$5.23-2.20 SummaryIntellia Therapeutics beats ADC Therapeutics on 9 of the 17 factors compared between the two stocks. Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADCT vs. The Competition Export to ExcelMetricADC TherapeuticsMED IndustryMedical SectorNYSE ExchangeMarket Cap$312.41M$2.94B$5.56B$20.65BDividend YieldN/A2.42%5.06%3.72%P/E Ratio-2.1820.8528.2627.84Price / Sales4.42300.55435.9542.37Price / CashN/A42.1137.1222.32Price / Book-1.507.638.044.57Net Income-$157.85M-$55.05M$3.19B$989.30M7 Day Performance13.26%8.43%3.62%0.20%1 Month Performance-12.59%8.14%5.98%5.53%1 Year Performance-17.28%1.62%29.39%10.30% ADC Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADCTADC Therapeutics1.5396 of 5 stars$3.16-4.2%$7.75+145.3%-17.3%$312.41M$70.84M-2.18310News CoverageGap DownNTLAIntellia Therapeutics4.3519 of 5 stars$10.25-4.6%$33.37+225.5%-55.3%$1.11B$57.88M-1.96600AMPHAmphastar Pharmaceuticals4.3368 of 5 stars$22.86-1.5%$32.33+41.4%-44.0%$1.09B$731.97M8.282,028WVEWAVE Life Sciences4.5498 of 5 stars$7.06+1.6%$20.50+190.4%+37.0%$1.08B$108.30M-8.40240AUPHAurinia Pharmaceuticals3.0508 of 5 stars$7.47-1.6%$11.50+53.9%+56.9%$1.03B$235.13M26.68300Positive NewsARDXArdelyx4.1314 of 5 stars$4.35+1.9%$10.89+150.3%-23.8%$1.02B$333.61M-19.7790Analyst RevisionELVNEnliven Therapeutics2.822 of 5 stars$19.59-5.5%$41.20+110.3%-9.3%$1.02BN/A-10.2050Insider TradeVERVVerve Therapeutics3.0606 of 5 stars$11.16-1.1%$14.57+30.6%+63.9%$1.01B$59.61M-5.29110NAGENiagen Bioscience1.3498 of 5 stars$12.44-2.1%$19.50+56.8%+333.0%$1.00B$99.60M73.18120DYNDyne Therapeutics3.4007 of 5 stars$8.18-6.6%$41.13+402.8%-79.2%$995.72MN/A-2.28100Analyst ForecastHigh Trading VolumeCDTXCidara Therapeutics4.1372 of 5 stars$48.30-1.0%$57.14+18.3%+340.2%$983.59M$1.27M-1.6490Positive NewsAnalyst ForecastGap UpHigh Trading Volume Related Companies and Tools Related Companies NTLA Alternatives AMPH Alternatives WVE Alternatives AUPH Alternatives ARDX Alternatives ELVN Alternatives VERV Alternatives NAGE Alternatives DYN Alternatives CDTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ADCT) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ADC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADCT Stock Alerts